Danish biotech Breye Therapeutics has closed an oversubscribed EUR 67.5 million Series A financing to advance danegaptide, its first-in-class oral treatment for non-proliferative diabetic retinopathy (NPDR), into a Phase II clinical trial.

Egetis Therapeutics has received FDA approval for Emcitate (tiratricol), making it the first approved treatment in the US for patients with the rare genetic disease MCT8 deficiency. With the approval, the company also received a Rare Pediatric Disease Priority Review Voucher.

The company is investing USD 2 billion in Summit Therapeutics and launching a clinical collaboration that will combine Summit’s PD-1/VEGF bispecific antibody ivonescimab with AstraZeneca’s antibody drug conjugates (ADCs), starting in gastrointestinal cancers.

The company has signed a new contract with a leading US hospital network that operates multiple hospitals in the eastern United States. The contract covers an initial installation of 60 next-generation TetraGraph systems for monitoring patients under anaesthesia.

Arjo has presented a new strategy at its Capital Markets Day, committing to improve EBIT by approximately SEK 350 million (±25 million) compared with 2025, by mid-2029.

The company is to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company, provisionally named ‘Mölnlycke Surgical’, while Wound Care and Antiseptics continue as Mölnlycke.

Swedish biotech company MucoShield is developing a locally administered, fast-acting treatment to protect the oral mucosa during chemotherapy and prevent severe chemotherapy-induced oral mucositis, one of the most painful and debilitating side effects of cancer treatment.

BioArctic’s Alzheimer’s drug Leqembi is now available at a private clinic in Stockholm, where the first patient in Sweden to receive the drug outside a clinical trial started treatment on September 22. This comes five months after the NT Council advised Sweden’s regions against using it.

Elicera Therapeutics has received approval from the Swedish Medical Products Agency (Läkemedelsverket) to move its CARMA study of the CAR T-cell therapy ELC-301 in B-cell lymphoma into Phase IIa.

SciLifeLab is increasing its space on Campus Solna by more than 9,000m². Property owner Akademiska Hus is investing approximately SEK 230 million in an extensive renovation that will give the research center more modern laboratories, flexible workspaces, and new facilities for meetings and training.

Cancer rates among adults under 50 rose for 12 of 18 cancer types in the Nordic countries between 2003 and 2022, according to a registry study published in The Lancet Regional Health – Europe. The study analyzed more than 2.2 million cancer cases from Sweden, Denmark, Finland, Iceland, Norway, the Faroe Islands and Greenland, covering nearly 28 million people.

Patients who have had high-risk polyps removed can probably wait five years rather than three for their first follow-up colonoscopy without raising their risk of colorectal cancer. That is the finding from the European Polyp Surveillance (EPoS) trial, the world’s largest randomized study of follow-up after polyp removal, led from Oslo University Hospital and the University of Oslo. The first results were published in the New England Journal of Medicine.